Key Highlights
- CMND-100 successfully achieved its primary safety endpoint in a Phase I/IIa clinical study targeting Alcohol Use Disorder
- The latest cohort demonstrated excellent safety and tolerability with zero serious adverse events reported, including at maximum tested doses
- Shares of CMND surged more than 100%, reaching approximately $1.44 following the news
- The multinational study has FDA approval and assesses safety, tolerability, and preliminary efficacy in patients with moderate to severe AUD
- After examining safety data, the Data and Safety Monitoring Board authorized the trial to proceed
Shares of Clearmind Medicine (CMND) experienced a dramatic rally on Monday, climbing more than 100% after the biotechnology company revealed that CMND-100, its flagship drug candidate, successfully achieved the primary safety endpoint in an FDA-sanctioned Phase I/IIa clinical study for Alcohol Use Disorder.
At the time of reporting, the stock was changing hands near $1.44, representing an approximate 100% gain for the session.
Results from the trial’s third cohort revealed impressive safety and tolerability characteristics, even when participants received the highest dosage levels tested to date. The company reported zero serious adverse events throughout the cohort.
According to Clearmind, these findings aligned with data from previous cohorts, indicating that the drug maintains its favorable safety profile as dosage levels escalate.
CMND-100 represents a non-hallucinogenic, oral therapeutic candidate based on MEAI. The company is advancing it as a potential treatment for individuals suffering from moderate to severe Alcohol Use Disorder.
The ongoing Phase I/IIa study spans multiple countries and clinical sites. Its objectives include evaluating safety, tolerability, pharmacokinetic properties, and initial efficacy signals.
Significant Milestone Achieved
Successfully meeting the primary safety endpoint during the dose-escalation phase represents a critical milestone. According to Clearmind, this achievement validates the continued development of CMND-100 as a viable therapeutic option.
The company’s Data and Safety Monitoring Board conducted a thorough review of the accumulated safety data and granted approval for the trial to move forward. To date, 18 participants have completed both treatment and follow-up protocols.
Clearmind’s research strategy centers on neuroplastogen-derived treatments that avoid the hallucinogenic properties typically associated with psychedelic-based therapies.
Company’s Current Position
Prior to Monday’s surge, the stock had experienced a steep decline of nearly 50% during the previous week. Shares were valued at only $0.72, with the company’s market capitalization hovering around $1.5 million.
Financially, the company maintains more cash reserves than outstanding debt and possesses liquid assets exceeding its near-term liabilities. This positioning provides the company with operational flexibility as it advances its clinical programs.
Clearmind’s intellectual property holdings encompass 19 patent families and 31 issued patents. Most recently, the company submitted a patent application to the Indian Patent Office covering psychedelic-derived compounds intended for mental health and addiction treatment applications.
This latest filing connects to a licensing arrangement with Yissum Research Development Company, which serves as the technology transfer organization for the Hebrew University of Jerusalem.
CMND was trading at $1.44, up 100.06%, at time of publication, according to Benzinga Pro data.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
